| |
| Virtual Event – R&D Leadership During the Pandemic |
| | Date: Tuesday, June 9, 2020 Time: 10:00am ET
Join Endpoints at BIO as they host a virtual fireside discussion and panel where R&D execs from Amgen, GSK, Janssen, Takeda, and Catalent discuss how they’ve reorganized global teams, tapped new programs as a priority to fight COVID-19, and what they plan for the future after the pandemic. A BIO registration pass is not required to attend! |
|
|
|
|
|
|
| This 90-minute event will start with a fireside chat with Laurie H. Glimcher, President & CEO, Dana-Farber Cancer Institute, followed by a panel discussion moderated by John Carroll, Founder & Editor of Endpoints News, and including leaders from across the pharma industry:
- David Reese, Executive VP, R&D, Amgen
- Hal Barron, CSO & President, R&D, GlaxoSmithKline
- Mathai Mammen, Global Head of R&D, Johnson & Johnson
- Andrew Plump, President, R&D, Takeda
- John Chiminski, Chair & CEO, Catalent
|
|
|
|
| | |
|
|
| |
| |
| Arcturus Therapeutics and Catalent Biologics to Discuss How COVID-19 Is Changing Technologies and Partnerships |
| | Attending BIO Virtual June 8-12? View this presentation on-demand to learn about how the COVID-19 pandemic is changing technologies and partnerships in the pursuit to develop a vaccine. |
|
|
|
|
|
|
| Title: How COVID-19 Is Reshaping Vaccine Development: Innovations in Vaccine Technology and Manufacturing Partnerships
Speakers: - Jared Davis, Ph.D., Vice President of Technical Operations and Manufacturing, Arcturus Therapeutics
- Graham Brearley, Ph.D., General Manager, Madison, Catalent Biologics
|
|
|
|
| | |
|
|
| Abstract: It is clear that broad social change, science-driven development and strong partnerships will be required to combat this public health crisis in the near term, but there will also be long term benefits from this period of accelerated innovation. During this presentation, experts from Arcturus Therapeutics and Catalent Biologics will provide an update on their partnership to enable and expedite scale-up to large-scale manufacturing, how it applies to the pandemic, and how it can be applied to future vaccine development. |
|
|
|
|
|
|
| |
| Every molecule has a challenge. We have a solution. |
| | | | or call +1 877 891 9609 to speak with one of our experts today! |
| | |
|
|
|
|
|
| |
| To unsubscribe or manage your subscriptions, please click here.
For more information call +1-866-720-3148 or in Europe 00800 88 55 6178, email us at sales@catalent.com, or visit our website www.catalent.com. And to learn more about Career opportunities across our global network, visit www.catalent.com/careers . Catalent Pharma Solutions respects your privacy. Links to third party sites are provided as a convenience only. Catalent makes no representation or warranty about the technology, security or any content available at these sites. Links are not intended to imply Catalent's affiliation or endorsement of the website, its owner(s) or the content. © 2020, Catalent Pharma Solutions, Inc. 14 Schoolhouse Road, Somerset, NJ 08873. All rights reserved. |
|
|
|
|
|
|
| |
 |
